Longevity Lab Report · Public evidence card
How large was the magnesium bisglycinate sleep result?
Assessed 2026-11-15 · Main study published 2025-08-30
This card contains the public evidence assessment only.
Conclusion
The trial found a small additional improvement in reported insomnia symptoms over four weeks. It did not establish an objective sleep benefit or superiority to other magnesium forms.
- Population and design
- 155 adults aged 18–65 with self-reported poor sleep. Randomized, double-blind, placebo-controlled trial.
- Studied intervention
- Magnesium bisglycinate providing 250 mg elemental magnesium daily; this describes the trial, not a suggested dose.
- Comparator
- Placebo capsules.
- Measured outcome
- Change in the Insomnia Severity Index, a questionnaire. Follow-up: Four weeks.
- Observed result
- Scores fell 3.9 points with magnesium and 2.3 with placebo. The additional decrease was 1.6 points; P=0.049 and reported effect size d=0.2.
- Main limitations
- Questionnaires measure reported symptoms, not sleep stages or minutes measured in a laboratory.
- The small, short trial did not compare magnesium forms.
- Baseline magnesium status was not directly measured.
Baseline evidence assessment, not a new study or a revised library grade. This card contains no personal responses and does not recommend treatment.
Sources
- Bisglycinate sleep trial (Schuster et al., 2025)
Main study · Published 2025-08-30 · Checked 2026-11-15 · PMID 40918053
Primary publication results, limitations and disclosures via indexed PMC and publisher text
- Magnesium insomnia trial (Abbasi et al., 2012)
Context · Published 2012-12 · Checked 2026-11-15 · PMID 23853635
Primary publication abstract and indexed results
- Systematic review (Mah and Pitre, 2021)
Context · Published 2021-04-17 · Checked 2026-11-15 · DOI 10.1186/s12906-021-03297-z
Original systematic review, indexed full text
Public card: https://longevitylabreport.com/research/magnesium-sleep/card
Full explainer, context and assessment history